Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

Background: In Crohn’s disease and ulcerative colitis, the anti-α4β7 integrin antibody vedolizumab has demonstrated efficacy in phase III trials and has been successfully used under real-world conditions. Occasionally, it has also been used in other forms of inflammatory bowel disease (IBD) such as...

Cijeli opis

Bibliografski detalji

Glavni autori:	Laura Besendorf, Tanja M. Müller, Carol-Immanuel Geppert, Ines Schneider, Laura Mühl, Imke Atreya, Francesco Vitali, Raja Atreya, Markus F. Neurath, Sebastian Zundler
Format:	Artigo
Jezik:	Inglês
Izdano:	SAGE Publishing 2022-06-01
Serija:	Therapeutic Advances in Gastroenterology
Online pristup:	https://doi.org/10.1177/17562848221098899
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!